Latest Articles

Publication Date
Exosomal miR-22-3p targets p53 to regulate endometrial epithelial cell function in the pathogenesis of endometriosis.

Endometriosis (EMs) is a widespread gynecological disease, affecting approximately 6-10% of females of child-bearing age. Despite its significant influence on women's health, the specific pathophysiology remains unclear. The enrichment of …

Published: Sept. 4, 2026, midnight
Risk factors for a marked decline in anti-Müllerian hormone after minimally invasive ovarian cystectomy: A retrospective cohort study.

This study aimed to investigate the factors affecting the decline of serum anti-Müllerian hormone (AMH) in reproductive-aged women following minimally invasive ovarian cystectomy. A retrospective cohort study was conducted using …

Published: Sept. 2, 2026, midnight
Procedure-specific environmental microbiological monitoring in IVF laboratories: the SMILE multicenter study.

Environmental microbiological monitoring is mandatory in IVF laboratories; however, procedure-specific risk assessment across the entire medically assisted reproduction workflow remains limited. This multicenter study, named "SMILE" (Study of Environmental Microbiological …

Published: Sept. 2, 2026, midnight
Beyond listening: Social media as support, story, and influence in the endometriosis experience.

Social media has emerged as a valuable source of patient-generated data, offering insights into the lived experiences of individuals with endometriosis. While social listening research provides important perspectives on pain, …

Published: Sept. 1, 2026, midnight
The Phendo Project: How FemTech Is Advancing Endometriosis Research and Women's Health.

FemTech continues to evolve and advance despite persistent research and funding gaps. In this News and Perspectives article, JMIR Correspondent Jenny Castillo Cato reports on an innovative, cross-disciplinary research project …

Published: Aug. 26, 2026, midnight
A transcriptomics-based computational drug repurposing pipeline identifies simvastatin and primaquine as therapeutics for endometriosis.

Endometriosis has limited treatment options, prompting the search for data-driven therapeutics. We previously used a transcriptomics-based computational drug repositioning pipeline and identified several drug candidates. Fenoprofen, our top in silico …

Published: Aug. 21, 2026, midnight
Role of oral gonadotropin-releasing hormone antagonists in the management of uterine adenomyosis: a narrative review.

In women with uterine adenomyosis, bleeding and pain can have a major impact on quality of life. There is clearly widespread demand for effective long-term medical therapies. The objective of …

Published: Aug. 14, 2026, midnight
Endometriosis presenting as recurrent massive haemorrhagic ascites.

Haemorrhagic ascites (HA) is an uncommon clinical entity commonly caused by cirrhosis, malignancy and iatrogenic intervention. In the absence of these causes, it poses a diagnostic challenge. We present a …

Published: Aug. 13, 2026, midnight
Cannabis-Based Medicinal Products for Endometriosis: A 2-Year Prospective Analysis From the UK Medical Cannabis Registry.

Endometriosis affects up to 10% of biological females of reproductive age. Current treatment options are limited and often unsuitable for prolonged use. Cannabis-based medicinal products (CBMPs) have emerged as an …

Published: Aug. 12, 2026, midnight
Hormonal therapies for endometriosis-associated pain: inflammatory limitations and pharmacological challenges.

Endometriosis is a chronic inflammatory and estrogen-dependent disease in which pain remains the leading cause of impaired quality of life. Hormonal therapies constitute the cornerstone of medical management and include …

Published: Aug. 11, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!